Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: A systematic review and meta-analysis

Journal of Clinical Oncology

Volumn 31, Issue 33, 2013, Pages 4188-4198

  Moorman, Patricia G ^a   Havrilesky, Laura J ^a,b   Gierisch, Jennifer M ^a,c,d   Coeytaux, Remy R ^a,d   Lowery, William J ^a   Urrutia, Rachel Peragallo ^e   Dinan, Michaela ^d   McBroom, Amanda J ^d   Hasselblad, Vic ^a   Sanders, Gillian D ^d   Myers, Evan R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COCHRANE LIBRARY; DISEASE ASSOCIATION; EMBASE; EVALUATION STUDY; FAMILY HISTORY; GENE MUTATION; HIGH RISK PATIENT; HUMAN; MEDLINE; META ANALYSIS; OVARY CANCER; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; FEMALE; GENETICS; HETEROZYGOTE; MUTATION; OVARY TUMOR; REVIEW; CHEMICALLY INDUCED;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL; FEMALE; HETEROZYGOTE; HUMANS; MUTATION; OVARIAN NEOPLASMS; RISK ASSESSMENT;

EID: 84892948632     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.9021     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
2. Kosary CL: Cancer of the Ovary, in Ries LAG, Young JL, Keel GE, et al (eds): SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. NIH Pub. No. 07-6215. Bethesda, MD, National Cancer Institute, SEER Program, 2007, pp 133-144
3. Buys SS, Partridge E, Black A, et al: Effect of screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305:2295- 2303, 2011
4. Altekruse SF, Kosary CL, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2007. Based on November 2009 SEER data submission, posted to the SEER web site, 2010. Bethesda, MD, National Cancer Institute. http://seer.cancer.gov/csr/ 1975-2007/
5. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003 (Pubitemid 36530000)
6. Antoniou AC, Cunningham AP, Peto J, et al: The BOADICEA model of genetic susceptibility to breast and ovarian cancers: Updates and extensions. Br J Cancer 98:1457-1466, 2008 (Pubitemid 351543573)
7. Permuth-Wey J, Sellers TA: Epidemiology of ovarian cancer. Methods Mol Biol 472:413-437, 2009
8. Rebbeck TR, Kauff ND, Domchek SM: Metaanalysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80- 87, 2009
9. Kurian AW, Munoz DF, Rust P, et al: Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 30:497-506, 2012
10. Grann VR, Patel PR, Jacobson JS, et al: Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat 125:837-847, 2011
11. Hickey M, Ambekar M, Hammond I: Should the ovaries be removed or retained at the time of hysterectomy for benign disease? Hum Reprod Update 16:131-141, 2010
12. Atsma F, Bartelink ML, Grobbee DE, et al: Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: A meta-analysis. Menopause 13:265-279, 2006
13. Havrilesky LJ, Gierisch JM, Moorman PG, et al: Oral Contraceptive Use for the Primary Prevention of Ovarian Cancer: Evidence Report/Technology Assessment No. 212. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No. 13-E002-EF. Rockville, MD, Agency for Healthcare Research and Quality, June 2013. http://effectivehealthcare.ahrq. gov/ehc/ products/416/1528/cancer-ovarian-contraceptivesreport- 130607.pdf
14. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R, et al: Ovarian cancer and oral contraceptives: Collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303-314, 2008
15. Peragallo Urrutia R, Coeytaux RR, McBroom A, et al: Risk of acute thromboembolic events with oral contraceptive use: A systematic review and meta-analysis. Obstet Gynecol 122:380-389, 2013
16. Gierisch J, Coeytaux R, Peragallo Urrutia R, et al: Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: A systematic review. Cancer Epidemiol Biomarkers Prev (in press)
17. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies - Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 347:1713-1727, 1996
18. Agency for Healthcare Research and Quality: Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(12)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. April 2012. www.effectivehealthcare.ahrq.gov
19. Borenstein M, Hedges L, Higgins J, et al: Comprehensive Meta-analysis Version 2 Englewood, NJ, Biostat, 2005
20. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986 (Pubitemid 17189972)
21. Antoniou AC, Rookus M, Andrieu N, et al: Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: Results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 18: 601-610, 2009
22. Brohet RM, Goldgar DE, Easton DF, et al: Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 25:3831-3836, 2007 (Pubitemid 47477257)
23. McGuire V, Felberg A, Mills M, et al: Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 160:613-618, 2004 (Pubitemid 39281840)
24. Whittemore AS, Balise RR, Pharoah PD, et al: Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91:1911-1915, 2004 (Pubitemid 40065520)
25. Gronwald J, Byrski T, Huzarski T, et al: Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 95:105-109, 2006
26. McLaughlin JR, Risch HA, Lubinski J, et al: Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: A case-control study. Lancet Oncol 8:26-34, 2007 (Pubitemid 46001033)
27. Modan B, Hartge P, Hirsh-Yechezkel G, et al: Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345:235-240, 2001 (Pubitemid 32695062)
28. Narod SA, Dubé MP, Klijn J, et al: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94:1773-1779, 2002 (Pubitemid 36004353)
29. Milne RL, Knight JA, John EM, et al: Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 14:350-356, 2005 (Pubitemid 40270096)
30. Haile RW, Thomas DC, McGuire V, et al: BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50 Cancer Epidemiol Biomarkers Prev 15:1863-1870, 2006 (Pubitemid 44664261)
31. Lee E, Ma H, McKean-Cowdin R, et al: Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: Results from a population-based study. Cancer Epidemiol Biomarkers Prev 17:3170-3178, 2008
32. Figueiredo JC, Haile RW, Bernstein L, et al: Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: The WECARE Study. Breast Cancer Res Treat 120:175-183, 2010
33. Bernholtz S, Laitman Y, Kaufman B, et al: Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutation. Breast Cancer Res Treat 129:557-563, 2011
34. Tavani A, Ricci E, La Vecchia C, et al: Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer. Int J Epidemiol 29:799-802, 2000
35. Chiaffarino F, Pelucchi C, Parazzini F, et al: Reproductive and hormonal factors and ovarian cancer. Ann Oncol 12:337-341, 2001 (Pubitemid 32288689)
36. Walker GR, Schlesselman JJ, Ness RB: Family history of cancer, oral contraceptive use, and ovarian cancer risk. Am J Obstet Gynecol 186:8-14, 2002 (Pubitemid 34093732)
37. Heimdal K, Skovlund E, Møller P: Oral contraceptives and risk of familial breast cancer. Cancer Detect Prev 26:23-27, 2002 (Pubitemid 36087178)
38. Grabrick DM, Hartmann LC, Cerhan JR, et al: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 284:1791-1798, 2000
39. Silvera SA, Miller AB, Rohan TE: Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: A prospective cohort study. Cancer Causes Control 16:1059-1063, 2005 (Pubitemid 41356003)
40. Bosetti C, Negri E, Trichopoulos D, et al: Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 102:262-265, 2002 (Pubitemid 35222295)
41. Narod SA, Risch H, Moslehi R, et al: Oral contraceptives and the risk of hereditary ovarian cancer: Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339:424-428, 1998 (Pubitemid 28377683)
42. Mavaddat N, Barrowdale D, Andrulis IL, et al: Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 21:134-147, 2012
43. Atchley DP, Albarracin CT, Lopez A, et al: Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282-4288, 2008
44. Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases - Breast Cancer Linkage Consortium. Lancet 349:1505-1510, 1997